Eli Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction To Daily Insulin Degludec In Phase 3 QWINT-2 Trial; Results Published In NEJM And Presented At EASD 2024; Efsitora Reduced A1C By 1.34% Compared To 1.26% For Insulin Degludec
Eli Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction To Daily Insulin Degludec In Phase 3 QWINT-2 Trial; Results Published In NEJM And Presented At EASD 2024; Efsitora Reduced A1C By 1.34% Compared To 1.26% For Insulin Degludec
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7%
在 qWint-2 中，efsitora 幫助對胰島素治療天真的成年人目前正在使用和未使用 GLP-1 受體激動劑的 A1C 降至 7% 以下
Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
詳細結果發表在《新英格蘭醫學雜誌》上，並同時在2024年歐洲糖尿病研究協會（EASD）年會上發表
INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naïve). The data were published in The New England Journal of Medicine (NEJM) and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.
印第安納波利斯，2024年9月10日 /PRNewswire/ — 禮來公司（紐約證券交易所代碼：LLY）今天公佈了QWint-2三期試驗的詳細結果，該試驗評估了首次使用胰島素的2型糖尿病成年人每週一次的efsitora alfa（efsitora），與首次使用胰島素（胰島素天真）的2型糖尿病成人每天服用一次胰島素的比較。這些數據發表在《新英格蘭醫學雜誌》（NEJM）上，並於今天在歐洲糖尿病研究協會（EASD）2024年年會上同時發佈。
In the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand1,2, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of 6.87% and 6.95% respectively3 at 52 weeks.
在試驗中，efsitora達到了非劣質A1C還原的主要終點。據估計，功效1,2，efsitora將A1C降低了1.34％，而胰島素degludec的A1C爲1.26％，因此在52周時，A1C分別爲6.87％和6.95％3。
Additionally, participants taking efsitora achieved 45 minutes more time in range4 per day, a key secondary endpoint, without additional time in hypoglycemia (glucose <54 mg/dL) in comparison to insulin degludec for the efficacy estimand.
此外，在療效評估中，服用efsitora的參與者在每天4範圍內的時間延長了45分鐘，這是一個關鍵的次要終點，與degludec胰島素相比，沒有額外的低血糖時間（葡萄糖